The positive data gives Eli Lilly the green light to file the drug with the FDA by the end of the year for a weight loss indication.

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...

An analyst's bullish new note on Lockheed Martin (NYSE: LMT) and the wider U.S. defense sector provided lift to the company's ...

Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...

Labcorp, one of the largest laboratory service providers in the world, performs hundreds of millions of tests per annum. Read ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

In a report released today, David E. Strauss from Barclays maintained a Buy rating on L3Harris Technologies (LHX – Research Report), with a ...

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company entered into a definitive merger ...

Is A Potential Trade War on the Horizon? The US stock market […] With President Donald Trump announcing a wide set of tariffs, there could be increased costs for a range of companies.